Crocs shares plunge due to declining Q3 sales, tariff impact, and shifting consumer behavior, leading the company to adjust its strategy to protect brand health and profitability.
Decades after 9/11, advanced DNA testing identifies three more victims, providing closure to families.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.
Crocs shares plunge due to declining Q3 sales, tariff impact, and shifting consumer behavior, leading the company to adjust its strategy to protect brand health and profitability.
Decades after 9/11, advanced DNA testing identifies three more victims, providing closure to families.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.